论文部分内容阅读
目的评价氟罗沙星序贯疗法与静脉滴注疗法治疗泌尿系感染的成本-效果分析,为临床制定合理用药方案提供参考。方法将86例泌尿系感染患者随机分为氟罗沙星序贯组与静脉滴注输液组,观察两组的疗效并进行经济学分析。结果两组在临床疗效及细菌学清除率方面无显著性差异(P>0.05),但在费用方面输液组明显高于序贯组(P<0.05)。结论氟罗沙星序贯疗法是治疗泌尿系感染的较佳方案。
Objective To evaluate the cost-effectiveness analysis of sequential and intravenous drip therapy of fleroxacin in the treatment of urinary tract infection, and to provide a reference for the rational formulation of the drug. Methods Eighty-six patients with urinary tract infection were randomly divided into fleosafine sequential group and intravenous drip infusion group. The curative effect of the two groups was observed and the economic analysis was conducted. Results There was no significant difference in clinical efficacy and bacteriological clearance between the two groups (P> 0.05). However, the cost of transfusion group was significantly higher than that of sequential group (P <0.05). Conclusion The sequential therapy of fleroxacin is the best treatment for urinary tract infection.